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Targeting of Lymphotoxin-a to the Tumor Elicits
an Efficient Immune Response Associated
with Induction of Peripheral Lymphoid-like Tissue
mounts an effective cellular response against murine
melanoma (Becker et al., 1996; thor Straten et al., 1998a).
However, detailed studies revealed that, although an-
tibody-IL-2 fusion proteins were able to boost a pre-
existing T cell response, the induction of additional tu-
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LTa exists either as a soluble or membrane-bound
Summary molecule. The soluble form is a homotrimer and binds
to the receptors TNFRI and TNFRII (Loetscher et al.,
A recombinant antibody-lymphotoxin-a fusion protein 1990), for which TNFa is also a ligand, whereas the
induced an adaptive immune response protecting membrane-bound form of LTa is a heterotrimer com-
mice from melanoma. Importantly, this fusion protein plexed with the transmembrane protein lymphotoxin-b
elicited the formation of a lymphoid-like tissue in the (LTb) (Browning et al., 1993). The LTa/b complex (LTa1/
tumor microenvironment containing L-selectin1 T cells LTb2) cannot bind to either of the TNF receptors but
and MHC class II1 antigen-presenting cells, as well as instead serves as a ligand for the LTb receptor (LTbR)
B and T cell aggregates. Furthermore, PNAd1/TCA41 (Crowe et al., 1994).
high endothelial venules were observed within the tu- Several studies revealed the important function of
mor, suggesting entry channels for naive T cell infil- lymphotoxin in lymph node genesis. Notably, LTa/b–
trates. Over the course of therapy, a marked clonal LTbR interactions seem to be most relevant, as disrup-
expansion of certain TCR specificities occurred tion of either the LTb or LTbR genes led to the absence
among tumor-infiltrating lymphocytes that displayed of Peyer’s patches and most lymph nodes (Rennert et
reactivity against melanoma cells and the TRP-2180–188 al., 1996; Koni et al., 1997). In comparison, in mice
peptide. Consequently, naive T cells may have been treated with antibodies against LTbR and TNFRI as well
recruited to as well as primed and expanded in the as in LTa knockout mice, no lymph nodes were observed
lymphoid-like tissue induced by the lymphotoxin-a fu- at all (De Togni et al., 1994; Rennert et al., 1998), implying
sion protein at the tumor site. that LTa–TNFRI interactions rescued some of the lymph
node genesis in LTb knockout mice. Furthermore, it has
been shown that expression of LTa under the controlIntroduction
of a rat insulin promoter induced a lymphoid-like tissue
at the site of expression in transgenic mice, designated a
A variety of tumors have proven to be immunogenic, tertiary lymphoid organ (Kratz et al., 1996). This lymphoid
and for melanoma, several tumor-associated antigens neogenesis was mediated by LTa through induction of
have been identified, some of which are recognized by several adhesion molecules as well as chemokines in
specific T cells. However, in most cases, despite detect- endothelial cells (Ruddle, 1999).
able anti-tumor responses, these do not control estab- Initial studies of a tumor-specific antibody-LTa fusion
lished tumor growth. Therefore, many anti-tumor thera- protein were performed in a xenograft melanoma model
peutic strategies aim at enhancing these existing T where this treatment was effective in eliminating pulmo-
cell–based immune responses (Keilholz and Eggermont, nary metastases (Reisfeld et al., 1996). Additional experi-
2000). In this regard, earlier studies have shown that ments in mice with different immune defects demon-
the genetic fusion of a tumor-specific antibody with a strated a dependence of the therapeutic effect on B
cytokine is a powerful tool to enrich the cytokine in the lymphocytes and NK cells. These results encouraged
tumor environment, thus taking the paracrine working us to examine the effect of the antibody-LTa fusion
mechanism of cytokines into account (Reisfeld et al., protein in an autologous murine melanoma model and
1997). We previously demonstrated that antibody-medi- thereby to scrutinize the working mechanisms of di-
ated targeting of IL-2 to the tumor microenvironment rected LTa therapy.
We demonstrate that antibody-LTa fusion protein
therapy is an effective treatment resulting in the eradica-k To whom correspondence should be addressed (e-mail: becker-
jc.derma@mail.uni-wuerzburg.de). tion of established pulmonary metastases and subcuta-
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Table 1. Effect of the ch14.18-LTa Fusion Protein on Experimental Lung Metastasesa Depending on Time of Initiation of Therapy as
well as Dose and Specificity of the Antibody-LTa Fusion Protein
Treatment
Initiation [d]b Dosec Number of Focid,e Lung Weight [g]
3 10 ng sLTa 79, 101, .200, .200, .200, .200, .200, .200 0.60 6 0.13
3 32 mg ch14.18 86, 134, 142, .200, .200, .200, .200, .200 0.54 6 0.11
32 mg ch225-LTa 49, 71, 102, 148, .200, .200, .200, .200 0.48 6 0.14
16 mg ch14.18-LTa 0, 74, 89, .200, .200, .200, .200, .200 0.42 6 0.11
32 mg ch14.18-LTa 0, 0, 0, 0, 0, 0, 0, 8 0.22 6 0.04
64 mg ch14.18-LTa 0, 0, 0, 0, 0, 0, 0, 43 0.29 6 0.08
3 32 mg ch14.18-LTa 0, 0, 0, 0, 0, 0, 0, 13 0.30 6 0.09
7 0, 0, 0, 0, 0, 0, 16, 34 0.37 6 0.10
10 0, 0, 16, 37, 52, 102, .200, .200 0.53 6 0.17
14 87, 101, 113, .200, .200, .200, .200, .200 0.66 6 0.10
a Experimental pulmonary metastases were induced in C57BL/6J mice by i.v. injection of 2.5 3 106 B78-D14 cells.
b Treatment was initiated at the indicated days after tumor cell inoculation.
c The therapy was administered by daily i.p. injections for 5 consecutive days.
d Animals were sacrificed and the metastatic score evaluated 35 days after tumor inductions.
e Each group consisted of eight animals.
neous tumors. Furthermore, our results suggest an im- ceptor (Figures 1A and 1B and Table 1). In contrast, mice
receiving 16 mg of ch14.18-LTa fusion protein alreadyproved T cell immune response, which is most likely
showed a reduction in size and number of the metastaticevoked by the induction of peripheral lymphoid tissue
foci indicated by lower lung weights. Moreover, at higherat the tumor site. In fact, the functional significance of
doses, i.e., 32 mg, almost all animals (14 of 16) exhibitedthis tertiary lymphoid tissue at tumor sites was con-
lungs completely free of metastases (Figure 1C), a find-firmed by immunohistologic and electron microscopic
ing that was confirmed by hemotoxylin/eosin-stainedanalysis of endothelial/lymphocyte interactions as well
sections (Figure 1D). An increase in the dose of ch14.18-as TCR clonotype mapping, providing evidence for the
LTa to 64 mg did not further improve the therapeuticinduction of new T cell clones among TIL, which were
effect. After establishing 32 mg as the amount ofshown to specifically lyse melanoma cells and to pro-
ch14.18-LTa necessary for successful treatment of pul-duce IFNg in response to a TRP-2 derived peptide.
monary metastases, we performed kinetic studies to
investigate the effect of ch14.18-LTa at various stages
of tumor progression. These experiments revealed thatResults
treatment with ch14.18-LTa could be delayed up to 1
week after induction of pulmonary metastases while stillTherapeutic Effect of Antibody-LTa Fusion Proteins
achieving a complete inhibition of tumor growth in 75%on Pulmonary Metastases
of the animals. However, the number of cured animalsInitially, we confirmed that the ch14.18-LTa fusion pro-
was reduced to 25% when therapy was started on daytein exerts direct cytotoxic effects against a number of
10, and no therapeutic effect was observed at this dosetumor cell lines in vitro as well as its antigen-specific
level when therapy began on day 14. These observationsbinding to the disialoganglioside GD2. Additionally, we
indicate that either changes in the microenvironment ofestablished that the specific activity of the ch14.18-LTa
tumors, established for more than 10 days, or the merefusion protein was three logs less than soluble LTa
size of the tumor burden at that stage of disease coun-(sLTa), as measured by killing of L929 cells (data not
teracted the effects induced by ch14.18-LTa.
shown).
In a subsequent series of experiments, we tested the
in vivo anti-tumor effect of this fusion protein upon ex- Eradication of Subcutaneous Tumors
perimental pulmonary metastases of B16 melanoma The second series of experiments evaluated the effect
cells, genetically engineered to express GD2, in synge- of ch14.18-LTa therapy on subcutaneous tumors. Mac-
neic C57BL/6J mice. The results of these experiments roscopic examination on day 28 revealed that treatment
are summarized in Table 1. Initially, the effect of different of animals with 64 mg ch14.18-LTa from day 14 through
doses of ch14.18-LTa fusion protein was established. 20 after tumor cell inoculation resulted in flattened and
Treatment was initiated on day 3 after tumor cell injec- necrotic tumors (Figure 2A). Such an effect on subcuta-
tion and maintained for 5 consecutive days. The lungs of neous tumors was never observed in control animals
control mice revealed a heavy metastatic burden when receiving comparable amounts of sLTa. This finding was
exposed to either 10 ng of sLTa—which corresponds confirmed by measurements of mean tumor volume over
to more than 10 times the lytic activity of ch14.18-LTa— the course of the experiment where three groups of
to 32 mg of the parental antibody ch14.18 or to 32 mg of eight mice each either received 10 ng sLTa or 32 mg
an antibody-LTa fusion protein directed to an irrelevant and 64 mg antibody-LTa, respectively. The mean tumor
volume of the control group constantly increased overantigen, i.e., ch225-LTa recognizing the human EGF re-
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Figure 1. Macroscopic, Histological, and Immunohistological Characterization of Tumor Specimens
Pulmonary metastases (A–D) were induced by i.v. and subcutaneous tumors (E–Q and S) by s.c. injection of 2.5 3 106 B78-D14 cells. For
pulmonary metastases, treatment was administrated from day 3 through 7, consisting of 10 ng sLTa (A and B) or 32 mg ch14.18-LTa (C and
D). For subcutaneous tumors, treatment was provided from day 14 through 21 with either 10 ng of sLTa (E and G) or 64 mg ch14.18-LTa (F,
H, I–Q, and S). On day 35, lungs were removed, their macroscopic appearance documented (A and C), and sections subsequently subjected
to hematoxylin/eosin staining (B and D). Subcutaneous tumors were excised on day 21 (E–J, N–Q, and S) or day 28 (K–M) after tumor induction.
In addition, lymph nodes of untreated mice (R and T) were obtained. Sections were subjected to staining with antibodies directed against
CD4 (E and F), CD8 (G and H), CD45R/B220 (M), CD62L (N and O), MHC class II (P), PNAd (Q and R), and TCA-4 (S and T). Double staining
was performed with an antibody directed to CD45R/B220 (I–L, blue) together with either anti-CD4 (I and K, red) or anti-CD8 (J and L, red)
antibodies. In (I–M), B cell aggregates are indicated by closed arrowheads, T cell aggregates by open arrowheads, and the tumor by arrows
(K–M). Scale bars: 25 mm (O), 100 mm (G–J, M, and T), 200 mm (D, K, and L), 400 mm (B), or 50 mm (all others).
the time course of therapy (Figure 2B). In contrast, tumor (p , 0.017) at a dose of 64 mg ch14.18-LTa as compared
to 10 ng sLTa. As was observed for pulmonary metasta-growth in ch14.18-LTa treated animals leveled off after a
few days of therapy. On day 21 the mean subcutaneous ses, the effect of ch14.18-LTa on subcutaneous tumors
was dose dependent.tumor volume of the ch14.18-LTa treated groups started
to decrease, and on day 28 the reduction in tumor vol- It should be noted that the mean tumor volume started
to increase again 9 days after therapy was stopped.ume between treated and control groups was significant
Immunity
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Figure 3. Kaplan-Meier Plot Demonstrating the Effect of ch14.18-
LTa Fusion Protein on the Life Span of C57BL/6J Mice Bearing
Pulmonary Metastases
Each group consisted of six animals. The control group received
10 ng of sLTa (solid line) and the therapy group 32 mg ch14.18-
LTa fusion protein (dashed line) from days 3 through 7 after tumor
inoculation. The experiment was terminated on day 112.
metastases and was administered for 5 consecutive
days. In the control group, death started to occur at day
47. In contrast, at day 62 when the last mouse of the
control group had died, all of the ch14.18-LTa treated
mice still remained alive. In fact, only one animal in
the ch14.18-LTa treated group died (day 85) prior to
termination of the experiment on day 112 (Figure 3).
Infiltration of Naive T Cells into
ch14.18-LTa–Treated Tumors
Several experiments were performed to delineate theFigure 2. Effect of ch14.18-LTa Therapy on Subcutaneous Tumors
mechanisms involved in the observed anti-tumor effectC57BL/6J mice were injected s.c. with 2.5 3 106 B78-D14 melanoma
of the antibody-LTa fusion protein. Initially, we charac-cells. Therapy with either 32 mg or 64 mg ch14.18-LTa for 7 consecu-
terized the tumor-infiltrating lymphocytes (TIL) by immu-tive days was started at day 14 after tumor cell inoculation. Control
animals received 10 ng sLTa. Macroscopic appearance of the tumor nohistochemistry. When tumor sections were stained
on day 28 in an animal treated with 10 ng sLTa (left) or 64 mg with antibodies against CD4 and CD8, few if any positive
ch14.18-LTa (right) (A). Mean tumor volumes of animals (n 5 8) cells were observed in tumors obtained from control
receiving 10 ng sLTa (open circles), 32 mg (closed triangles), and 64
animals (Figures 1E and 1G). In contrast, ch14.18-LTamg (closed squares) ch14.18-LTa, respectively (B). Individual tumor
treated mice revealed a marked infiltration of CD41 Tvolumes of all animals treated with 64 mg ch14.18-LTa are given
cells throughout the tumor, whereas CD81 T cells accu-separately (C).
mulated at the tumor periphery (Figures 1F and 1H). We
performed flow cytometry to quantitate the difference
in inflammatory infiltrates between control animals andAnalysis of the individual tumor volumes, however, pro-
vided a more detailed picture. In fact, in five of eight mice ch14.18-LTa–treated mice. To this end, in addition to
the larger magnitude of inflammatory infiltrate, we foundtreated with 64 mg ch14.18-LTa, the tumor regressed
completely in response to ch14.18-LTa administration a much higher percentage of both CD41 and CD81 T
cells in TIL from ch14.18-LTa treated mice, whereas inand did not reoccur within the observation period of the
experiment. The remaining three animals revealed tumor control animals the infiltrate was dominated by NK cells
(data not shown). Detection of B cells by immunohisto-regressions persisting for several days before the tumor
started to grow again (Figure 2C). chemistry with the CD45R/B220 monoclonal antibody
revealed their presence in the tumor as small cell aggre-
gates starting on day 21 (Figures 1I and 1J). Notably, 7Antibody-LTa Fusion Protein Treatment
Prolongs Survival days later, B cells were concentrated in a lymphoid-like
pattern adjacent to the tumor in the majority of analyzedSurvival studies were performed to determine whether
the observed anti-tumor effect of the antibody-LTa fu- samples (Figures 1K–1M). Moreover, CD41 and CD81 T
cells were enriched next to these structures. To deter-sion protein would translate into a prolonged survival.
Each experimental group consisted of six animals. The mine whether the infiltrate resembled the cellular com-
position of a lymphoid tissue, we stained sections ofcontrol group was treated with 10 ng sLTa, whereas the
therapy group received 32 mg ch14.18-LTa. Treatment the tumor with an antibody directed against MHC class
II to identify antigen-presenting cells. MHC class II1 cellswas started 3 days after the induction of pulmonary
Lymphotoxin-Dependent Lymphoid Neogenesis
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Figure 4. Electron Microscopy of Tumor
Blood Vessels
Subcutaneous tumors were induced by s.c.
injection of 2.5 3 106 B78-D14 cells in C57BL/
6J mice. After 14 days, animals received ei-
ther 10 ng of sLTa (A) or 64 mg ch14.18-LTa
(B–D) for 7 consecutive days. Endothelial
cells in tumors of control animals appear flat
(A, 33,000), while those of the therapy group
display a cuboidal shape (B, 33,000). At
higher magnification, lymphocytes migrating
through the vessel wall (C, 312,000) and lym-
phocyte–endothelial interaction mediated by
microvilli (D, 324,000) are depicted.
were found dispersed throughout the tumor and many for blood vessels in tumors of ch14.18-LTa treated mice
and HEV in lymph nodes of normal mice (Figures 1Sdisplayed dendritic cell–like morphology (Figure 1P). We
further stained for L-selectin since this molecule is ex- and 1T).
To confirm that some of the blood vessels penetratingpressed on a subset of lymphocytes composed of
mainly naive T cells for which it serves as a homing the tumor were HEV, we performed electron microscopy
studies. Blood vessels in all untreated tumors pos-receptor to lymph nodes. Indeed, L-selectin1 cells were
found throughout the tumor (Figure 1N). Furthermore, sessed the phenotype of peripheral capillaries with flat
endothelia (Figure 4A). In contrast, tumors treated withat higher magnification, L-selectin1 cells were detected
in close contact with endothelial cells (Figure 1O), sug- antibody-LTa fusion protein harbored vessels with HEV
morphology, i.e., endothelial cells of cuboidal shapegesting expression of L-selectin ligands on tumor ves-
sels subsequent to ch14.18-LTa therapy. Tissues of (Figure 4B). In addition, we observed lymphocytes trans-
migrating out of the vessel lumen through the junctionscontrol animals stained essentially negative for the anti-
bodies tested (data not shown). between high endothelial cells (Figure 4C). At higher
magnification, interactions between high endothelial
venules and lymphocytes were observed to take placeHigh Endothelial Venule Characteristics of Blood
via microvilli (Figure 4D).Vessels of ch14.18-LTa Treated Tumors
Migration of L-selectin1 cells into tissue occurs through
specialized blood vessels, the high endothelial venules Clonotype Mapping Reveals an Increase
in the Number of T Cell Clones(HEV), which normally are limited to lymph nodes and
Peyer’s patches. As described above, we obtained evi- during the Course of Therapy
Since we detected lymphoid-like tissue, HEVs, and thedence that naive T cells may adhere and migrate through
tumor blood vessels after therapy with ch14.18-LTa. infiltration of CD62L1 T cells in tumors subsequent to
ch14.18-LTa administration, we tested the hypothesisTherefore, we stained for PNAd, an adhesion molecule
restricted to HEV that serves as ligand for L-selectin. that this treatment indeed alters the T cell response
against the tumor by priming and subsequently ex-About 30% of the vessels in tumors of ch14.18-LTa
treated mice (Figure 1Q) were stained in a similar pattern panding newly recruited cells. Such a change should
translate into differences in the T cell receptor (TCR)as HEV in lymph nodes (Figure 1R), the signal covering
the internal surface of the vessel. A further mandatory repertoire among TIL. Consequently, we analyzed the
relative expression of all TCR b-variable (BV) regionsstep for migration of naive T cells through HEV is the
activation of the lymphocytes via chemokine receptor prior to and after therapy. This was done by semiquanti-
tative PCR with specific primers for each murine TCR BVCCR7, mediated by TCA-4 (Exodus-2, SLC, 6Ckine),
which is present in the glycocalyx of HEV. Indeed, anti- family which demonstrated that treatment with ch14.18-
LTa induced a relative overexpression of some TCR BVTCA-4 antibodies revealed identical staining patterns
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families differing between animals (data not shown). In
addition to these differences in the relative overexpres-
sion, we also observed a major increase in the magni-
tude of the inflammatory infiltrate in general and in the
number of infiltrating T cells in particular (Figures 1F
and 1H). However, since we observed previously that
clonal expansion of T cells is not restricted to overex-
pressed TCR BV families but also occurs in nonoverex-
pressed regions (thor Straten et al., 1999), we estab-
lished the clonotype maps of BV regions 1–16 within the
same tumor over the course of the experiment. The
variable regions BV 17 and 18 were excluded, since
previous work indicated that these families comprise
less than 0.5% each of the total TCR transcripts (thor
Straten et al., 1998a). For these experiments, treatment
was started 8 days after tumor cell inoculation for 7
consecutive days, and biopsies of the same tumor were
obtained on days 7, 14, and 21. Figure 5A depicts as
an example the TCR clonotype map of BV regions 1–16,
generated by RT-PCR/DGGE analysis of one ch14.18-
LTa–treated animal at day 21. Each distinct band repre-
sents an individual T cell clone. In some BV regions,
such as BV 5, only one or two clones were detected,
whereas in others there were up to seven, e.g., BV 8.
Comparative analysis of serial tumor biopsies demon-
strated the dynamics in the TCR repertoire of TIL
(Figure 5B). In fact, not only the persistence and the
induction of T cell clonotypes over the course of the
experiment was observed, but also the disappearance
of clonotypes present in TIL prior to therapy. To illustrate
the changes in the occurrence of clones, we provide
the ratios of the number of clones on day 14 and day
21 compared to day 7 (Figures 5C and 5D). For ch14.18-
Figure 5. TCR Repertoire Changes of TIL over the Course of
LTa treated animals, TCR clonotype mapping revealed Therapy
an increase in the number of T cell clones among TIL.
Subcutaneous tumors were induced by s.c. injection of 2.5 3106
These clones covered the majority of BV regions. How- B78-D14 cells in C57BL/6J mice. Treatment was administered from
ever, the increase in the number of T cell clones varied days 8–14 in the form of 64 mg ch14.18-LTa (A–C) or 10 ng of sLTa
(D). Biopsies of tumors were taken 7, 14, and 21 days after tumorbetween the BV regions, ranging from one (BV 2) to up
cell inoculation and analyzed by TCR clonotype mapping. Exampleto seven (BV 15). In contrast, although the occurrence
of a TCR clonotype map of TIL on day 21 of a ch14.18-LTa treatedof T cell clones in control animals was also diverse,
tumor covering BV regions 1–16 (A). Comparative TCR analysis forthere was no general increase in the number of T cell
BV families 2 and 15. Samples were obtained from the same tumor
clonotypes. localized on the right flank on day 7 (lane 1), day 14 (lane 2), and
In addition to tumor biopsies, the draining lymph day 21 (lane 3) as well as by excision of the inguinal lymph nodes
on day 21 (left and right, lanes 4 and 5, respectively) (B). The variationnodes were also analyzed at day 21. Even when all
in number of T cell clones for BV regions 1–16 is given as the ratioTCR BV regions were taken into account in these lymph
of the number of clones on day 14 (gray) or 21 (black) to the numbernodes, RT-PCR/DGGE clonotype mapping showed at
of clones on day 7 for ch14.18-LTa (C) and sLTa (D) treated animals.most a few faint bands (Figure 5B). This finding implies
that the T cell population in the lymph nodes is either
largely polyclonal or that the clonal expansion is below if these would indeed translate into a functional active
the detection level of the applied method. RT–PCR/ and specific T cell response. This was done by cytotox-
DGGE clonotype mapping, however, is generally able icity and ELISPOT assays. The cytotoxicity assays re-
to detect a T cell clone in a mixed population at a fraction vealed that peripheral blood lymphocytes (PBL) or TIL
of 0.1% (thor Straten et al., 1998b). Besides, in rare obtained from ch14.18-LTa treated mice after therapy
cases where T cell clones were present, these never were at least twice as efficient in killing B78-D14 mela-
matched with those clonotypes found in the tumor. noma cells compared to lymphocytes derived from con-
trol animals (Figures 6A and 6B). The specific killing of
B78-D14 was MHC class I restricted, as it could beInduction of a Specific T Cell Response
by ch14.18-LTa Therapy inhibited by the presence of a surplus of C3H antibody
directed against the MHC I molecules H2-Kb and H2-Db.The immunological changes induced by ch14.18-LTa
therapy, including an altered inflammatory infiltrate, infil- Thereafter, we analyzed the ability of the CD81 T cells
among PBL and TIL to react against a defined tumor-tration of CD62L1 T cells into tumors, as well as the
clonal expansion of certain TCR BV specificities subse- associated antigen, i.e., TRP-2, a melanocyte differ-
entiation antigen. This reactivity was measured in thequent to ch14.18-LTa therapy, prompted us to examine
Lymphotoxin-Dependent Lymphoid Neogenesis
117
Figure 6. Presence of Specific Cytotoxic and
IFN-g-Producing T Cells in PBL and TIL
The percentage of lysed B78-D14 melanoma
cells by PBL (A) or TIL (B) was measured at
different effector to target ratios in a 51Cr re-
lease assay as previously described (Becker
et al., 1996). Effector cells were obtained sub-
sequent to treatment with either 10 ng sLTa
(open diamonds) or 64 mg ch14.18-LTa
(closed squares). For cells obtained from
ch14.18-LTa treated animals, the assay was
also performed in the presence of the anti-
H2-Kb/H2-Db monoclonal antibody C3H (closed
triangles). In the ELISPOT assay, either 105
CD81 T cells isolated from PBL (C) or 104
CD81 cells from TIL (D) obtained after treat-
ment with either 10 ng sLTa (1) or 64 mg
ch14.18-LTa (2) were analyzed after 5 days
of in vitro culture for their reactivity against
the TRP-2180–188 epitope. Each spot represents
an IFN-g-producing cell. Graphs depict the
quantification of reactive cells; gray columns
represent the average number of IFN-g-pro-
ducing cells in the absence of peptide, white
columns those in the presence of the TRP-
2180–188 peptide.
ELISPOT assay by the production of IFN-g induced in al., 1999). Thus, a syngeneic model was required to
delineate such mechanisms in more detail. To this end,response to RMA-S cells pulsed with the TRP-2180–188
epitope. Reactivity against this TRP-2 peptide epitope we observed a marked infiltrate of T lymphocytes subse-
quent to therapy with ch14.18-LTa in the syngeneicwas present in both control animals and mice treated
with ch14.18-LTa. This observation indicates that the model. Additional lines of evidence indicating that T
cells are the principal effector cells induced by targeted-presence of B78-D14 melanoma alone induces a detect-
able cellular immune response, a notion substantiated LTa therapy included the presence of MHC class I re-
stricted B78-D14 specific cytotoxic T cells and the de-by the presence of clonally expanded T cells in untreated
tumors (Moerch et al., 2000). The amount of reactive T tection of TRP-2180–188 reactive IFN-g-producing cells in
PBL and TIL. The latter observation is of particular inter-cells, however, was more than three times higher among
samples derived from animals treated with ch14.18-LTa est since it rules out the possibility that the induced T
cell response is only directed against the target antigenthan those of control animals receiving 10 ng sLTa. In
PBL from ch14.18-LTa–treated mice, we detected an of the ch14.18-LTa fusion protein, i.e., the disialogangli-
oside GD2. The difference in recruitment of effector cellsaverage of 208 TRP-2 peptide-specific spots per 105
CD81 cells. In contrast, for sLTa treated control animals in the xenograft and syngeneic tumor models is likely
due to a xenogeneic response in the former (Brouard etthis number was only 36 (Figure 6C). The specific reactiv-
ity of CD81 cells obtained from TIL was more than one al., 1999).
Immunohistological stainings of the tumor subse-log higher than those from PBL. Thus, the ELISPOT
assay performed with only 104 CD81 T cells revealed quent to treatment did not only reveal a marked T cell
infiltrate but also indicated the segregation of T and B293 TRP-2180–188 peptide-specific spots for ch14.18-LTa
treated and 91 spots for control animals (Figure 6D). The cells in defined areas. This observation prompted us to
test the hypothesis that targeted LTa therapy may in-background reactivity against unpulsed RMA-S cells in
the assays performed with TIL was rather high and is duce the neogenesis of lymphoid tissue at the tumor
site, allowing the recruitment of naive T cells. In thismost likely due to remaining T cell epitopes derived from
contaminating tumor cells in the T cell preparation. regard, L-selectin can be used as a marker for naive T
cells, which serves them as a homing receptor to HEV
in secondary lymphoid organs via its interaction withDiscussion
the adhesion molecule PNAd (Salmi et al., 1998). Subse-
quent to ch14.18-LTa treatment, L-selectin1 cells wereWe previously reported the therapeutic effect of a tumor-
specific antibody-LTa fusion protein in a xenograft tu- found dispersed all over the tumor as well as being in
direct contact with endothelial cells. In addition, manymor model (Reisfeld et al., 1996). Here, we demonstrate
the efficacy of this immunocytokine against B16 mela- of the vessels within the tumor expressed PNAd, which
is normally restricted to HEV (Premier and Meeusen,noma, leading to the eradication of both pulmonary me-
tastases and subcutaneous tumors in a syngeneic tumor 1998). Moreover, the lumen of the vessels was covered
with TCA-4, another molecule largely confined to HEV.model. In the xenograft model, the effect of the antibody-
LTa fusion protein was found to be dependent on B and TCA-4 reacts with the CCR7 chemokine receptor on T
cells and upregulates LFA-1 (Stein et al., 2000); thisNK cells. However, in xenograft tumor models multiple
confounding factors may obscure the actual working activation is mandatory for the firm arrest of T cells after
their initial rolling during the process of extravasationmechanism of immunomodulatory agents (Robson et
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of naive T cells from the bloodstream into lymphoid strong presumptive evidence that the therapy-induced
tertiary lymphoid organ is functional and allows for prim-tissues (Stein et al., 2000). Further evidence was pro-
vided by electron microscopy studies that clearly con- ing of naive lymphocytes at the tumor site. Thus, the
effects of antibody-LTa therapy differ substantially fromfirmed the HEV morphology of z30% of blood vessels
in the tumor. Taken together, these findings imply that the effects induced by the antibody-IL-2 fusion protein
therapy that only boosted a preexisting T cell responsenaive T cells migrated from blood into the tumor micro-
environment subsequent to ch14.18-LTa therapy. These (thor Straten et al., 1998a). Nevertheless, for both thera-
pies the eradication of B78-D14 tumors is mediated viaobservations are consistent with a report by Kratz et al.
(1996) stating that the basis of the chronic inflammation clonally expanded tumor-specific T cells rather than a
polyclonal, nonspecific T cell population. As in the casecaused by lymphotoxin is lymphoid neogenesis. These
investigators demonstrated that the structures gener- of antibody-IL-2 treatment, targeted-LTa therapy is
closely linked to tumor regression, raising the questionated by the transgenic expression of LTa under the
control of a rat insulin promoter resembled lymph nodes whether the emergence of new clones is directly related
to the treatment or a secondary phenomenon reflectingwith regard to cellular composition, delineated T and B
cell areas, primary and secondary follicles, and charac- the immunological rejection. However, separate analy-
sis of regressive and progressive parts of human mela-teristic morphologic as well as antigenic features of HEV.
Thus, it appears likely that treatment with the antibody- noma lesions did not reveal differences in the numbers
of clonotypic T cells, indicating that immunological re-LTa fusion protein induces a lymphoid-like tissue at the
site of LTa accumulation in the tumor. It has previously jection is not coupled to the presence of higher numbers
of clonotypic T cells (thor Straten et al., 1996). Moreoverbeen shown that the presence of inflammation induced
by transgenic expression of LTa is not dependent on the last tumor samples for TCR clonotype mapping were
obtained at day 21, a time when the progressive growthLTb expression, although its cellular composition is in-
fluenced by this cytokine (Sacca et al., 1998; Cuff et al., of the tumor just started to level off; thus, the presence
of clonally expanded T cells is at least not caused by1999). Since sLTa can be generated by the cleavage of
a plasmin site in the ch14.18-LTa fusion protein, LTa1b2 tumor necrosis but rather is a therapy-induced immune
response.complexes may form at the tumor site subsequent to
ch14.18-LTa therapy. Therefore, future experiments in The finding that almost no clones were discovered in
the draining lymph nodes further suggests that primingLTb knockout mice are planned to address the question
whether LTa1b2 complexes are involved in the therapeu- occurred in the tumor and not in the lymph node. Fur-
thermore, even when we were able to detect an occa-tic effect of ch14.18-LTa.
Lymphoid tissue is the prime environment for initiating sional clonal expansion within these lymph nodes, none
of these were identical to those present in the tumorT cell responses (Lakkis et al., 2000), as naive T cells are
only able to encounter antigen in such tissues (Cyster, (Figure 5B). Our results agree with those of a recent
report by Shrikant and Mescher (1999), who demon-1999). Hence, the question whether the lymphoid tissue
induced by antibody-LTa fusion protein therapy would strated that transferred, transgenic cytotoxic T lympho-
cytes only expand at the site of antigen. This holds alsopromote the clonal expansion of infiltrating T cells was
of pertinent importance. To this end, analysis of the true for viral infections where virus-specific CD81 T cells
are only predominating the T cell pool at sites of viralT cell clonality by RT–PCR/DGGE clonotype mapping
revealed an increase in the number of clones over the replication (Flynn et al., 1998). In humans, we were able
to detect identical T cell clonotypes in the primary tumorcourse of treatment. This was not observed in control
animals. Comparative clonotype analysis demonstrated and in the sentinel lymph node (unpublished results),
whereas in the present murine model this was not possi-that this increase in the number of clonally expanded
T cells is due to both the persistence as well as the ble. While most human melanoma tumor cells have the
capacity to disseminate and to cause metastases, theoccurrence of new clones. It should be noted that the
clonotypic composition of TIL in untreated tumors was B78-D14 cell line used in the present murine model was
derived from a B16 subline that does not spontaneouslynot static either, but neither quantitative nor qualitative
analysis could divulge a significant change during the metastasize (Stackpole, 1981). Therefore, melanoma
cells present in the sentinel lymph node of patients maycourse of the experiment. It is not possible to establish
with certainty whether clones emerging during the cause primed T cells to expand, whereas in our mouse
model no tumor cells were found in the lymph node.course of treatment are truly “new” or represent the
amplification of preexisting clones that were previously The induction of lymphoid tissues at the tumor site
should provide the means to overcome two of the majorbelow the level of detection. However, large numbers
of polyclonal transcripts hamper the detection of a T obstacles to prolonged immune responses to weakly
immunogenic tumors, i.e., clonal anergy and clonal ex-cell clonotype, leaving a clone more likely to be left
undetected in treated tumors that were characterized haustion (Fields et al., 1996). It may avoid T cell anergy by
provision of a suitable cytokine and cellular environmentby a brisk infiltration of T cells. Conversely, even minor
expansions are readily detected in untreated tumors together with a high antigen load. Clonal exhaustion may
be prevented, as new, naive T cells can be continuouslycharacterized by a limited infiltration of polyclonal T cells
(Moerch et al., 2000). Furthermore, T cell clones de- primed. The function and specificity of the resulting T
cell response was conclusively shown. Nevertheless,tected in lymph nodes draining the tumor were never
detected recurrently in the tumor. This observation, to- the recurrent observation that even high doses of
ch14.18-LTa fusion protein did not cure all animals maygether with the immunohistological and electron micro-
scopical evidence for the occurrence of HEV and inter- be due to differences in the quality and/or quantity of
clonal T cell responses. The magnitude of a T cell re-action of lymphocytes with the endothelia, provides
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by injection of tumor cells, mice were anesthetized by halothanesponse is at least theoretically dependent on the fre-
inhalation; tumor cells were suspended in 500 ml PBS containingquency of suitable T cell precursors (Bousso and Kouril-
0.1% BSA and administered i.v. over a period of 60 s. After 7 days,sky, 1999). Animals that cannot be cured may possess
micrometastases were disseminated throughout the lungs, invading
a lower frequency of T cell precursors, or the induced the pulmonary alveoli. At day 28, grossly visible metastases were
T cell response may be characterized by insufficient present on the surface of the organ. At day 35, lungs were fixed in
antigen binding specificity. In addition, other immune Bouin fixative and examined under a low magnification microscope
for tumor foci on their surface. Sections from the lungs were stainedescape mechanisms have to be taken into consideration
with hematoxylin/eosin and examined histologically.(Marincola et al., 2000).
Antibody-LTa dependent lymphoid neogenesis may
Subcutaneous Tumorsimprove anti-tumor responses in several ways. The pos-
Tumors were induced by s.c. injection of 2.5 3 106 B78-D14 mela-
sibility that naive T cells can be primed next to the tumor noma cells in RPMI 1640, which resulted in tumors of approximately
by a tertiary lymphoid organ should lead to (1) a larger 40 ml volume within 14 days.
number of primed tumor-specific T cells since tumor-
specific antigens predominate (Flynn et al., 1998), (2) a Treatment Schedule
Soluble LTa or the ch14.18-LTa fusion protein was administeredreduction in the time between priming and expansion
daily either by i.p. injections for pulmonary metastases or by i.v.as well as the risk of primed T cells not reaching the
injections for subcutaneous tumors. For pulmonary metastasestumor, and (3) ongoing T cell responses that react more
therapy was maintained for 5 days and subcutaneous tumors for 7readily and quickly to changes in the antigen expression days. The applied dose is specified for each individual experiment
profile of the tumor. In addition, it may stop lymphocytes in the Results. Murine anti-human antibodies directed against the
from leaving the tumor microenvironment, which is ben- chimeric fusion protein do occur but are likely to have only an impact
on additional cycles of therapy.eficial since it has been suggested that effective immu-
notherapy depends more on sustaining an immune re-
Immunohistochemistrysponse at the appropriate location than on its initiation
Frozen sections were fixed in cold acetone for 10 min, followed by(Shrikant and Mescher, 1999). Thus, the effectiveness
removal of endogenous peroxidase with 0.03% H2O2 and blockingof tumor-targeted LTa therapy appears to be due to
of collagenous elements with 10% species-specific serum. All stain-
direct clonal expansion of tumor-specific T cells through ings were performed with the techmate automate (Dako, Hamburg,
the formation of peritumoral lymphoid tissue. Germany). For single staining, serial sections were incubated for 30
min with biotinylated antibodies at predetermined dilutions (usually
Experimental Procedures 20 mg/ml). Subsequently, the streptavidin-peroxidase complex
(DAKO) was applied for 30 min, followed by a 15 min incubation
Animals with the Chromogen AEC (DAKO). Finally, slides were counter
C57BL/6J mice were obtained from Charles River Laboratories stained. For double staining, the last step was replaced by a 30 min
(Sulzfeld, Germany) at the age of 6 weeks. These animals were incubation with an additional antibody, its detection by a species-
housed under specific pathogen-free conditions and all experiments specific alkaline phosphatase-coupled secondary antibody during
were performed according to National Institute of Health guidelines a 30 min incubation followed by the use of the Chromogen AP blue
for care and use of laboratory animals. substrate kit (Zytomed, Berlin, Germany). Between each incubation
step the slides were washed with Tris buffer. After a final wash
Cell Line, Antibodies, and Fusion Proteins with water, the slides were mounted in aquatex (Merck Eurolab,
The murine melanoma cell line B78-D14 has been described pre- Darmstadt, Germany).
viously (Haraguchi et al., 1994). B78-D14 was derived from B16
melanoma by transfection with genes coding for b-1,4-N-acetylga- Electron Microscopy
lactosaminyltransferase and a-2,8-sialyltransferase, inducing a con- Tumors were dissected in 0.1 M cold sodium cacodylate buffer (pH
stitutive expression of the disialogangliosides GD2 and GD3. B78-
7.2) containing 3% glutaraldehyde and 1.7 mM CaCl2. After washingD14 melanoma cells were maintained as monolayers in RPMI 1640
in the same buffer supplemented with 3% sucrose, the tissue was
medium supplemented with 10% fetal calf serum, 2 mM L-glutamine,
postfixed for 1 hr on ice with 2% osmium tetroxide and 1% potas-
400 mg/ml G418, and 50 mg/ml Hygromycin B. Cells were passaged
sium ferrocyanide in sodium cacodylate buffer. Subsequently, the
when subconfluent.
tissue was washed first with cacodylate buffer and then with 200
The mouse/human chimeric antibody directed against GD2
mM of sodium acetate buffer (pH 5.2). After staining for 1 hr with
(ch14.18) was constructed by joining the cDNA for the variable re-
1% uranyl acetate in sodium acetate buffer, the sample was dehy-gion of the murine 14.18 antibody with the constant regions of the
drated in ethanol, after which it was infiltrated with and embeddedhuman g1 heavy chain and the k light chain. From this, the ch14.18-
in EMBED 812 (EM Sciences, Gibbstown, NJ). Thin sections wereLTa fusion protein was constructed by fusion of a synthetic se-
examined with a Leo 906 electron microscope (Leo Electron Micros-quence coding for human LTa—lacking the leader peptide—to the
copy Ltd., Oberkochen, Germany).carboxyl end of the human Cg1 gene (Gillies et al., 1991). The fused
genes were inserted into the vector pdHL2, which encodes for the
TCR Clonotype Mapping by Denaturing Gradientdihydrofolate reductase gene. The resulting expression plasmids
Gel Electrophoresiswere introduced into Sp2/0-Ag14 cells and selected in Dulbecco’s
Denaturing gradient gel electrophoresis (DGGE) analysis for clono-modified Eagle’s medium supplemented with 10% fetal bovine se-
type mapping of the murine TCR BV regions 1–16 has been de-rum and 100 nM methotrexate. The fusion proteins were purified
scribed (thor Straten et al., 1998a). Briefly, RNA was extracted usingover a protein A–Sepharose affinity column.
the Purescript Isolation Kit (Gentra Systems Inc., Minneapolis, MN),All other antibodies used (anti-CD4, clone RM4-5; anti-CD8, clone
and synthesis of cDNA was carried out using 1–3 mg of total RNA,53-6.7; anti-CD45R/B220, clone RA3-6B2; anti CD62L, clone MEL-
oligo-dT, and SuperScript II reverse transcriptase (GIBCO–BRL,14; anti-PNAd, clone MECA-79 [Pharmingen, San Diego, CA]; anti-
Gaithersburg, MD). cDNA was amplified using primers specific forMHC-class II, clone M5/114 [ATCC, Rockville, MD]; and anti-TCA-4;
BV families 1–16 and a constant region primer. Amplified sequencesAF457 [R&D Systems, Wiesbaden, Germany]) are commercially
were evaluated using the computer program MELT87, which pre-available and have been described in detail by the manufacturer.
dicts the melting of a double-stranded DNA molecule on the basis
of its base composition (Lerman and Silverstein, 1987). These calcu-Experimental Lung Metastases
lations indicated that the DNA molecules amplified were suited forSingle cell suspensions of 2.5 3 106 B78-D14 cells were injected
into the lateral tail vein. To prevent pulmonary embolism caused denaturing gradient gel analysis by the attachment of a 50 bp GC-
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rich sequence to the 59 end of the constant region primer. Amplifica- Fields, P., Fitch, F.W., and Gajewski, T.F. (1996). Control of T lympho-
cyte signal transduction through clonal anergy. J. Mol. Med. 74,tions were performed in a GeneAmp PCR System 9700 (Applied
Biosystems, Weiterstadt, Germany) using previously described con- 673–683.
ditions. DGGE analysis was done in 6% polyacrylamide gels con- Flynn, K.J., Belz, G.T., Altman, J.D., Ahmed, R., Woodland, D.L., and
taining a gradient of urea and formamide from 20% to 80%. Electro- Doherty, P.C. (1998). Virus-specific CD81 T cells in primary and
phoresis was performed at 160 V for 4.5 hr in 13 TAE buffer at a secondary influenza pneumonia. Immunity 8, 683–691.
constant temperature of 548C.
Gillies, S.D., Young, D., Lo, K.M., Foley, S.F., and Reisfeld, R.A.
(1991). Expression of genetically engineered immunoconjugates of
ELISPOT Assay lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybrid-
The ELISPOT assay described by Taguchi et al. (1990) was modified oma 10, 347–356.
to detect TRP2180–188 specific CD8 T cells. First, 96-well filtration Haraguchi, M., Yamashiro, S., Yamamoto, A., Furukawa, K., Taka-plates (Millipore) were coated with rat anti-mouse IFNg antibody
miya, K., Lloyd, K.O., and Shiku, H. (1994). Isolation of GD3 synthase(clone R4-6A2, Pharmingen). Peptide-pulsed target cells were gen-
gene by expression cloning of GM3 a-2,8-sialyltransferase cDNAerated by incubating RMA-S cells, a TAP-deficient T cell lymphoma
using anti-GD2 monoclonal antibody. Proc. Natl. Acad. Sci. USA 91,line derived from C57BL/6J mice (B6, H-2b), with the appropriate
10455–10459.concentration of peptide for 45 min at room temperature. CD81 T
Keilholz, U., and Eggermont, A.M. (2000). The emerging role of cyto-cells were isolated from PBL or TIL as described (Becker et al.,
kines in the treatment of advanced melanoma. For the EORTC Mela-1996) and kept in culture for 5 days in complete medium supple-
noma Cooperative Group. Oncology 58, 89–95.mented with 10 units/well of recombinant human IL-2 (Chiron, Rat-
ingen, Germany) before being added at indicated numbers to 5 3 Koni, P.A., Sacca, R., Lawton, P., Browning, J.L., Ruddle, N.H., and
104 target cells. After 24 hr, the plates were washed, followed by Flavell, R.A. (1997). Distinct roles in lymphoid organogenesis for
incubation with biotinylated anti-mouse IFNg antibody (clone XMG lymphotoxins a and b revealed in lymphotoxin b-deficient mice.
1.2, Pharmingen). Spots were developed using freshly prepared Immunity 6, 491–500.
substrate buffer (0.3 mg/ml amino-9-ethyl-carbazole and 0.015% Kratz, A., Campos-Neto, A., Hanson, M.S., and Ruddle, N.H. (1996).
H2O2 in 0.1 M sodium acetate [pH 5]). Chronic inflammation caused by lymphotoxin is lymphoid neogene-
sis. J. Exp. Med. 183, 1461–1472.
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